Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease
- Author(s)
- Yeoh, DK; Blyth, CC; Kotecha, RS;
- Details
- Publication Year 2022-09,Volume 198,Issue #5,Page 887-892
- Journal Title
- British Journal of Haematology
- Publication Type
- Research article
- Abstract
- Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse. Blinatumomab, a bispecific T-cell engager targeting cells expressing CD19, has shown promise for treatment of relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and is associated with reduced toxicity compared to conventional chemotherapy. With close monitoring of minimal residual disease, we demonstrate that children with B-ALL can receive repeated cycles of bridging blinatumomab whilst conventional chemotherapy is withheld during treatment and recovery from IFD.
- Keywords
- *Antibodies, Bispecific/adverse effects; *Antineoplastic Agents/adverse effects; *Burkitt Lymphoma/drug therapy; Child; Humans; *Invasive Fungal Infections/drug therapy; *Lymphoma, B-Cell/drug therapy; Neoplasm Recurrence, Local/drug therapy; *Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/complications/drug therapy; *Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy; Remission Induction; acute lymphoblastic leukaemia; blinatumomab; immunotherapy; invasive fungal disease; paediatric
- Department(s)
- Infectious Diseases
- PubMed ID
- 35727917
- Publisher's Version
- https://doi.org/10.1111/bjh.18314
- Open Access at Publisher's Site
https://doi.org/10.1111/bjh.18314- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-16 05:12:11
Last Modified: 2025-05-16 05:13:40